Research article · 15 Apr 2026
Mini reviewPublished 31 Jan 2024
Targeting Inflammation to Slow CKD Progression- Role of Gut Microbiome Based Therapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chronic Kidney Disease (CKD) is a worldwide public health problem associated with high morbidity, mortality, and socioeconomic burden. Despite recent advances in pathogenesis and effective Standard of Care (SOC) therapy, the incidence of end stage renal disease remains high, attributed to the complex and diverse pathophysiological pathways in progression of CKD. Among the many pathogenetic pathways, inflammation plays the most central role in disease progression and related complications. Current SOC treatment to slow CKD progression has not adequately addressed these complex processes as a result of persistence of low-grade inflammation occurring at all stages of CKD. Previous attempts to address the inflammatory pathway with specific anti-inflammatory agents were, in certain cases discontinued for reasons ranging from drug safety to efficacy concerns, and business development decisions. Recent research findings demonstrating direct correlation between systemic inflammation associated gut microbiota changes and CKD progression, provided a potential novel therapeutic approach to target the inflammatory pathways. Exploring current scientific knowledge of modulating gut microbiome with microbiome-based therapies provides options in addressing these complex pathogenetic mechanisms of CKD-induced inflammation. The purpose of this minireview is to discuss the role of inflammation associated with gut microbiome changes in CKD progression and gut microbiome-based therapeutic options to slow CKD progression.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Emmanuel Anteyi”
- BylineArticles whose byline prints “Natarajan Ranganathan”
- BylineArticles whose byline prints “Usha Vyas”
